The trial is enrolling in the US and will include regions in the Asia Pacific, Europe, Latin America, and North America.

智通财经APP获悉，Deciphera Pharmaceuticals(DCPH.US)周一宣布，日本小野药品工业(OPHLY.US)已同意以24亿美元的总股本价值收购这家癌症药物开发商。受此消息提振，截至发稿，Deciphera 盘前大涨71%。 据悉，小野药品工业将通过要约收购方式，以每股25.60美元价格现金收购 ...

4月30日，小野制药（ONO Pharmaceutical）与Deciphera Pharmaceuticals宣布，双方达成确定性的合并协议。根据该协议，小野制药将斥资约24亿美元收购Deciphera公司。这一收购将增强小野制药的肿瘤学研发管线。 Deciphera公司拥有激酶药物发现和开发的专长，以及在美国和欧洲 ...

Deciphera Pharmaceuticals今日宣布，已与ONO Pharmaceutical达成确定性的合并协议。根据该协议，ONO将斥资约24亿美元收购Deciphera。通过此次合并，ONO和Deciphera将加速实现它们的共同愿景，向全球患者提供创新药物。 Deciphera拥有激酶药物发现和开发的专长，以及在美国和 ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer ...

On a bad day for the stock market overall, Deciphera Pharmaceuticals (NASDAQ: DCPH) was quite the happy standout. Shares of the biotech closed more than 12% higher on Tuesday thanks to the launch of a ...

Deciphera Pharmaceuticals(DCPH.US)周一宣布，日本小野药品工业(OPHLY.US)已同意以24亿美元的总股本价值收购这家癌症药物开发商。受此消息提振，截至发稿，Deciphera 盘前大涨71%。 据悉，小野药品工业将通过要约收购方式，以每股25.60美元价格现金收购Deciphera普通股的 ...

OSAKA, Japan & WALTHAM, Mass., November 17, 2025--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the opening of a ...

In subsequent weeks, it has experienced a further slide in price. Changing hands at around $8.50 per share, it’s down 77% from where it was before the trial news, and about 85% below where it was at ...

Deciphera Pharmaceuticals (NASDAQ:DCPH) stock absolutely imploded in November. Shares lost more than two-thirds of their value virtually overnight. In November, Deciphera presented its clinical ...

The company reported $42.1 million in revenue for 2020, up from $25 million in 2019. Qinlock (ripretinib) was responsible for most of that revenue, including $38 million in the U.S. and $1.5 million ...